Investment
Features
FeesSafety
Academy
More
Pluang+

Theralase closes $2.66M financing to advance cancer drug trials and regulatory filings.

Company Fundamentals
10 Apr 2026
Newsfile Corp
View Source
Bullish
pluang ai news

Theralase Technologies Inc. successfully closed a $2.66 million financing round through a private placement and a $1 million revolving line of credit. The funds will support ongoing Phase II clinical trials for bladder cancer, toxicology studies for their drug Rutherrin®, and general corporate needs. The company plans to file new drug applications with Health Canada and the FDA in 2026 for marketing approval of its light-activated drug Ruvidar® targeting bladder cancer. This financing strengthens Theralase's balance sheet and advances its strategic development goals.

More News (TLT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App